InVentiv Health acquired ParagonRx, a consulting company specializing in pharma risk management and optimizing medication use. The acquisition is aimed at bolstering inVentiv's Risk Evaluation and Mitigation Strategy offering . In the past year, the network noted, more than a quarter of all new drug approvals in the US included an FDA-approved REMS program.

Arguing that most Americans don't know about the FDA's adverse events reporting program, Consumers Union said DTC ads should include a toll-free number that patients can use to report side effects to the FDA.

GlaxoSmithKline is in Congressional crosshairs over its marketing of Avandia, and investors arent happy either.

The American Medical Association announced it is partnering with Sermo, the online community for physicians.

Lyons Lavey Nickel Swift is rebranding as “LyonHeart” under its proprietary creative-strategic process dubbed “Disruption.”

Onyx and Bayers kidney cancer drug Nexavar (sorafenib) was also found to extend the lives of liver cancer patients in a clinical trial by almost three months, or 44%, doctors said.

InVentiv Health has acquired brand identity shop Addison Whitney.

The FDA will convene a joint panel of outside experts to examine the risks and benefits of Sanofi-Aventis’ antibiotic Ketek (telithromycin).

The FDA will convene a joint panel of outside experts to examine the risks and benefits of Sanofi-Aventis’ antibiotic Ketek (telithromycin).

Pfizer won’t be allowed to present new data on its closely watched developmental drug torcetrapib at the annual American Heart Association (AHA) meeting this week.

Novartis has asked the FDA to extend the review period for its highly anticipated developmental diabetes drug Galvus by three months to allow the agency to examine new clinical trials data.

Genentech has agreed to acquire its Xolair co-marketer, the Houston-based biotech firm Tanox, in a deal worth $919 million.

3M has agreed to sell-off its global pharmaceuticals business, which makes dermatology, women’s health, cardiology and respiratory treatments, for $2.1 billion.

Abbott has agreed to buy specialty firm Kos for $3.7 billion, a move that complements its cardiovascular franchise and boosts its pipeline.

The prices being paid in the recent rash of pharmaceutical acquisition deals are “breath-taking,” Schering-Plough CEO Fred Hassan said in an interview with Marketwatch.com.

The California attorney general’s office expanded its probe into the marketing of anti-psychotic drugs, serving subpoenas to Eli Lilly and Bristol-Myers Squibb, the companies have said.

Pfizer confirmed that its leading pipeline candidate torcetrapib raised blood pressure in clinical trial patients more than previously reported.

The California attorney general’s office expanded its probe into the marketing of anti-psychotic drugs, serving subpoenas to Eli Lilly and Bristol-Myers Squibb, the companies have said.

Behavioral change-focused relationship marketing firm HealthMedia announced today that it has acquired the consumer Web site MySelfHelp.com.

Nearly 40% of scientists researching diseases and cures at the National Institutes of Health (NIH) are considering new jobs to escape strict ethics rules, a recent survey said.